Chemical Component Summary

Name2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate
Identifiers[2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl] ethanoate
FormulaC12 H9 N3 O5 S
Molecular Weight307.28
TypeNON-POLYMER
Isomeric SMILESCC(=O)Oc1ccccc1C(=O)Nc2ncc(s2)[N+](=O)[O-]
InChIInChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)
InChIKeyYQNQNVDNTFHQSW-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count30
Chiral Atom Count0
Bond Count31
Aromatic Bond Count11

Drug Info: DrugBank

DrugBank IDDB00507 
NameNitazoxanide
Groups
  • approved
  • investigational
  • vet_approved
DescriptionNitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths [A31976]. Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses [A31977].
Synonyms
  • Nitaxozanid
  • Nitazoxanide
  • Nitazoxanidum
  • Nitazoxanida
  • Nitaxozanide
Brand Names
  • N/a
  • Nitazoxanide
  • Alinia
IndicationFor the treatment of diarrhea in adults and children caused by the protozoa <i>Giardia lamblia</i>, and for the treatment of diarrhea in children caused by the protozoan, <i>Cryptosporidium parvum</i> [FDA label]. Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency [FDA label, A31973, A31976].
Categories
  • Anti-Infective Agents
  • Antiparasitic Agents
  • Antiparasitic Products, Insecticides and Repellents
  • Antiprotozoals
  • Sulfur Compounds
ATC-CodeP01AX11
CAS number55981-09-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Pyruvate-flavodoxin oxidoreductaseMGKKMMTTDGNTATAHVAYAMSEVAAIYPITPSSTMGEEADDWAAQGRKN...unknownantagonist,inhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSDQUZWOY
PubChem41684
ChEBICHEBI:94807
ChEMBLCHEMBL1401